These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12130532)

  • 61. Chronic myelogenous leukemia.
    Druker BJ; Sawyers CL; Capdeville R; Ford JM; Baccarani M; Goldman JM
    Hematology Am Soc Hematol Educ Program; 2001; ():87-112. PubMed ID: 11722980
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Successful treatment with low-dose imatinib mesylate of therapy-related myeloid neoplasm harboring TEL-PDGFRB in a patient with acute promyelocytic leukemia.
    Asou N; Iwanaga E; Nanri T; Mitsuya H
    Haematologica; 2010 Sep; 95(9):e1. PubMed ID: 20807977
    [No Abstract]   [Full Text] [Related]  

  • 63. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21).
    Kulkarni S; Heath C; Parker S; Chase A; Iqbal S; Pocock CF; Kaeda J; Cwynarski K; Goldman JM; Cross NC
    Cancer Res; 2000 Jul; 60(13):3592-8. PubMed ID: 10910073
    [TBL] [Abstract][Full Text] [Related]  

  • 64. From bedside to bench: treatment for rare blood disorder yields clues to disease mechanism.
    Friedrich MJ
    J Natl Cancer Inst; 2003 Aug; 95(15):1102-3. PubMed ID: 12902432
    [No Abstract]   [Full Text] [Related]  

  • 65. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
    Walz C; Metzgeroth G; Haferlach C; Schmitt-Graeff A; Fabarius A; Hagen V; Prümmer O; Rauh S; Hehlmann R; Hochhaus A; Cross NC; Reiter A
    Haematologica; 2007 Feb; 92(2):163-9. PubMed ID: 17296564
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
    Helbig G; Kyrcz-Krzemień S
    Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
    [No Abstract]   [Full Text] [Related]  

  • 67. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim YJ; Min CK; Kim HJ; Eom KS; Kim DW; Lee JW; Min WS; Kim CC
    Blood; 2005 May; 105(9):3449-57. PubMed ID: 15657178
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
    Song YP; Fang BJ; Wei XD; Zheng S
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose.
    Breccia M; Cilloni D; Cannella L; Stefanizzi C; Tafuri A; Fama A; Santopietro M; Saglio G; Alimena G
    Cancer Chemother Pharmacol; 2009 May; 63(6):1161-3. PubMed ID: 18989670
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
    Ottmann OG; Pfeifer H
    Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
    [TBL] [Abstract][Full Text] [Related]  

  • 71. TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor.
    Tomasson MH; Williams IR; Hasserjian R; Udomsakdi C; McGrath SM; Schwaller J; Druker B; Gilliland DG
    Blood; 1999 Mar; 93(5):1707-14. PubMed ID: 10029600
    [TBL] [Abstract][Full Text] [Related]  

  • 72. STI571 (GLIVEC) induced hematologic, cytogenetic and molecular remission in a cml patient relapsing with accelerated phase after allogeneic stem cell transplantation.
    Consoli U; Milone G; Guido G; Consoli C; Palumbo GA; Giustolisi R
    Haematologica; 2002 Dec; 87(12):ECR37. PubMed ID: 12495908
    [No Abstract]   [Full Text] [Related]  

  • 73. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
    Helbig G; Stella-Hołowiecka B; Majewski M; Całbecka M; Gajkowska J; Klimkiewicz R; Moskwa A; Grzegorczyk J; Lewandowska M; Hołowiecki J
    Br J Haematol; 2008 Apr; 141(2):200-4. PubMed ID: 18307562
    [TBL] [Abstract][Full Text] [Related]  

  • 74. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder.
    Grand FH; Burgstaller S; Kühr T; Baxter EJ; Webersinke G; Thaler J; Chase AJ; Cross NC
    Cancer Res; 2004 Oct; 64(20):7216-9. PubMed ID: 15492236
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571.
    le Coutre P; Kreuzer KA; Na IK; Lupberger J; Holdhoff M; Appelt C; Schwarz M; Müller C; Gambacorti-Passerini C; Platzbecker U; Bonnet R; Ehninger G; Schmidt CA
    Blood Cells Mol Dis; 2002; 28(1):75-85. PubMed ID: 11987244
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
    Ito K; Tominaga K; Suzuki T; Jinnai I; Bessho M
    Int J Hematol; 2005 Apr; 81(3):242-5. PubMed ID: 15814335
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.
    Parmar S; Katsoulidis E; Verma A; Li Y; Sassano A; Lal L; Majchrzak B; Ravandi F; Tallman MS; Fish EN; Platanias LC
    J Biol Chem; 2004 Jun; 279(24):25345-52. PubMed ID: 15056660
    [TBL] [Abstract][Full Text] [Related]  

  • 78. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
    Decaudin D; de Cremoux P; Sastre X; Judde JG; Nemati F; Tran-Perennou C; Fréneaux P; Livartowski A; Pouillart P; Poupon MF
    Int J Cancer; 2005 Feb; 113(5):849-56. PubMed ID: 15499612
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacology of imatinib (STI571).
    Buchdunger E; O'Reilly T; Wood J
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S28-36. PubMed ID: 12528770
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
    Klejman A; Rushen L; Morrione A; Slupianek A; Skorski T
    Oncogene; 2002 Aug; 21(38):5868-76. PubMed ID: 12185586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.